Ustekinumab persistence high, safe at 12 months in ‘difficult-to-treat’ Crohn’s patients
Long-term ustekinumab effectively and safely treated most patients in a “difficult-to-treat” Crohn’s disease cohort, according to research presented at the European Crohn’s and Colitis Organization meeting.
www.healio.com